Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease in 2005, its first product developed using the nab technology. Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010), among others.

About ABRAXANE (R)

The U.S. Food and Drug Administration approved ABRAXANE (R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:9/20/2014)... 2014 /CNW/ - The issue: Mylan Pharmaceuticals ULC Canada, in ... its Mylan-Nitro Spray 0.4 mg/metered dose due to the product ... component. A missing "dip tube" could pose ... patient. This defect may lead patients to believe they are ... access it. Not receiving nitroglycerin could place them at risk ...
(Date:9/19/2014)... Pa. , Sept. 19, 2014  Today ... two new variable angle plating systems featuring its ... surgeons can adapt screw trajectory to match patient ... specific fragments of bone. The systems are being ... & Ankle Society (AOFAS) and the International Federation ...
(Date:9/19/2014)... Calif. , Sept. 19, 2014 Today, iHealth ... capital from Xiaomi Ventures, Ltd. for its first institutional ... to continue expanding iHealth,s global reach, accelerate growth and ...  As part of the investment, Xiaomi Ventures will join ... areas of cloud infrastructure and ecommerce. "We ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... , SAN DIEGO, Oct. 15 Prometheus Laboratories ... announced the nationwide commercial launch of three new ... Dx and ProOnc Mesothelioma Dx. Each of these ... microRNA technology. , "Prometheus has a long and ...
... HOLLYWOOD, Fla. and PRINCETON, N.J., Oct. 15 ... preclinical and pharmaceutical product development services and PharmaNet ... development services to innovative pharmaceutical, biotechnology, generic drug ... the completion of a business development and co-promotion ...
Cached Medicine Technology:Prometheus Launches ProOnc Dx Cancer Diagnostics 2Prometheus Launches ProOnc Dx Cancer Diagnostics 3Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance 2
(Date:9/21/2014)... of preterm birth the birth of an infant ... significant health problem that has increased over the past ... Control and Prevention (CDC), preterm birth affects nearly 500,000 ... in the U.S. While medical care has improved survival ... positively impact the neurodevelopmental outcomes of preterm infants. , ...
(Date:9/21/2014)... of the leading online stores of real and synthetic hair ... human hair lace wigs inspired by 6 famous celebrities. It’s ... latest celebrity hairstyles are. , For people who ... to choose from: a style of yaki straight lace wig, ... ombre red lace wig. People can go to the product ...
(Date:9/21/2014)... public health authorities focus on the physical activity benefits ... of Montreal reveals that for children, playing has no ... activity that is fun, done alone or with friends, ... pleasure, but also to combat boredom, sadness, fear, or ... play, authorities put aside several aspects of play that ...
(Date:9/21/2014)... Dry roasted peanuts are more likely to trigger an ... University study involving mice. , The researchers say that ... the dry roasting process are recognised by the body,s ... allergic immune response the next time it sees any ... the number of people with peanut allergies in the ...
(Date:9/21/2014)... The Laboratory Testing Services industry is composed ... on items ranging from consumer and food products to ... operators to ensure the safety and quality of their ... government safety regulations and consumer lawsuits have led to ... revenue briefly dipped in 2009 as the US economy ...
Breaking Medicine News(10 mins):Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Dry roasting could help trigger peanut allergy 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... Corporation announces the,release of its ground-breaking line ... with four medical-grade formulations. Optiprene HA and ... in surgical or examination,gloves, medical adhesives, latex ... for people with latex allergies. Optiprene HA+2 ...
... on the heart, study says , , THURSDAY, Dec. 11 (HealthDay ... warning sign for increased risk of cardiovascular problems decades later ... residents of a rural farming community in southwestern Japan found ... during a first examination in 1979 predicted the development of ...
... , , WASHINGTON, Dec. 11 ... 2008, based on the number of people needing shelter, food, and ... flooding in the Midwest, and the tornadoes which devastated Indiana. ... disastrous part in many people,s lives in 2008. A record number ...
... researchers have discovered that a chemical known as endoxifen ... effectiveness of tamoxifen in treating breast cancer, and that ... , Their study, being presented at the Cancer Therapy ... annual San Antonio Breast Cancer Symposium, finds that, in ...
... Liverpool Associates in Tropical Health (LATH), a consulting arm ... a 10 million contract to manage a programme of ... initiative in Malawi. , Led by the National ... 5 year programme supported by the Wellcome Trust, the ...
... TCM Inc. of West Chester, PA ... named PCM Solutions, LLC, with Nalco Company ... the process industries, such as chemical and petrochemical manufacturing, ... paper manufacturing, food and beverage production, and various other ...
Cached Medicine News:Health News:Yulex Introduces Optiprene Medical-Grade Natural Rubber Emulsions Made From Its Safe and Natural Alternative to Hevea Latex 2Health News:Fast Heart Rate Warns of Obesity, Diabetes 2Health News:Fast Heart Rate Warns of Obesity, Diabetes 3Health News:Red Cross Announces Top Five Disaster Responses of 2008 2Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 2Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 3Health News:LATH wins contract to boost health research capacity in Malawi 2Health News:Haas TCM Inc. Forms PCM Solutions, LLC, a Joint Venture With Nalco Company, to Provide Chemical Management Services (CMS) to the Process Industries 2
... powerful, lightweight, easy to ... durable foam silicone rubber ... by machine washable cotton ... easily adjusts to all ...
... powerful, lightweight, easy to ... durable foam silicone rubber ... by machine washable cotton ... easily adjusts to all ...
Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear....
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Medicine Products: